HON 131.14    Updated: 04-28-2017 $HON Last Trade:

A Festive Transformation at CARNE Rolling into Oxnard, you're met with an unconventional dining spectacle at CARNE. It's not your average restaurant fare as they've pulled out the stops with their spirited Halloween pop-up, A Nightmare at CARNE. Channeling the eerie charm of "The Nightmare Before Christmas," this temporary transformation morphs the venue into a lively,...

Pioneering Path with IBI3001 at ESMO 2026 Navigating through the crowded landscape of oncology trials, Innovent Biologics recently rolled out some riveting Phase 1 clinical data for their new darling, IBI3001. Top brass from Innovent took to the European Society for Medical Oncology (ESMO) Congress stage to lay bare their findings. Obviously, when you're presenting a...

Massive Settlement: A Long-Awaited Justice Here's a different kind of news that's hitting like a thunderbolt. Over 1,300 survivors of abuse have finally struck a landmark deal with the Archdiocese of New York. Not only are the numbers staggering, but the relief for these individuals is palpable. We're talking about more than $800 million on the table here. That's some...

Satellite Services Take Off in the Middle East Never thought the day would come where the Middle East is on the threshold of leapfrogging satellite tech, but here we are. ST Engineering iDirect just locked arms with MBSat—yep, that's part of the Mohammed Al Barwani Group—to birth a next-gen satellite connectivity service hub in Oman and across surrounding areas....

Innovent Lauds HER2 ADC's Moment at ESMO 2026 Alright, chin up, investors. At the 2026 ESMO Congress, Innovent's throwing down some promising Phase 2 data for their brainchild, IBI354. You hear that name and it's like hearing about a rock star in the making in the oncology world. The potential here isn’t just talk—it's a loud, resounding call for attention. Their...

Prostate Cancer's Persistent Challenge No one in the healthcare game needs the reminder: prostate cancer is no walk in the park, especially for those grappling with advanced stages. Now picture this—you're on your sixth treatment, and the cloud is not lifting. It's a battle that never ends, with traditional therapies sometimes barely holding the line. JNJ-6143's New...

Breakthrough Results in SCLC Treatment For years, small cell lung cancer (SCLC) has been the unruly beast in the oncology world, defying treatment advances and keeping survival rates stubbornly low. This nasty foe might just have met its match, folks. Amgen (NASDAQ:AMGN) announced results from their Phase 3 DeLLphi-305 trial that show their drug IMDELLTRA®, when teamed...

Are Slim iPhone Cases Really Protecting Your Investment? Anyone who's dropped a brand-new phone knows the pain of watching your investment smack the concrete. But hey, welcome to 2026, where Consumer365's latest rundown on iPhone protective gear turns the spotlight on TORRAS. These folks grabbed attention with their Q3 Air and Q3 Air Pro cases, crafted for iPhone 18 Pro...

Cancer Care Takes Center Stage Kicking off with a bang in Abu Dhabi, Likang Life Sciences has made a splash in the world of personalized cancer immunotherapy. The Abu Dhabi Future Health Summit 2026 served as the backdrop for this bold move, lighting up discussions with their AI-enabled innovations. Likang's showing at the Summit wasn't just another walk in the park—it...

Wines Jockeying for New York’s Coveted Lists Alright, picture a stage set up in New York City like an arena. But instead of gladiators, you've got master sommeliers on one side and Italian wine producers on the other, each armed with their own arguments. They're locked in a battle over what it really takes to get a bottle imbedded on a New York City's prestigious wine...

Vor Bio Announces Exploration of Strategic Alternatives Today, Vor Bio, a clinical-stage cell and genome engineering company, has taken significant steps to enhance shareholder value. The decision comes at a time when the clinical data from its major programs suggests that reevaluating its approach could be beneficial in the face of challenging fundraising conditions....

Kraig Biocraft Laboratories' Milestone in Spider Silk Production Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB), a pioneering firm renowned for its innovative developments in spider silk-based fibers, is thrilled to share the successful conclusion of its fourth production cycle for the year. This cycle represents a remarkable achievement, showcasing record-breaking...

Gen X’s Coming Retirement Crunch Gen X—often called the “sandwich generation”—is being pulled in two directions at once and edging toward a retirement problem many don’t fully see. With money, time, and attention split between family and work, long-term savings can drift to the back burner. The worry isn’t abstract; it’s about whether the money will be...

Villa Spectre: A $55 Million Marvel of Luxury Living Villa Spectre has recently captured the spotlight as the highest-priced sale in the area, setting a remarkable benchmark in luxury real estate. This impressive estate was sold for $55,000,000, showcasing the allure and opulence that the elite have come to expect from high-end properties. A Visionary Creation Designed by...

Mosaic Minerals Re-prioritizes Focus on Gold Exploration Mosaic Minerals Corporation (CSE: MOC) is making a strategic pivot in its exploration efforts. The company has announced the cessation of its lithium exploration initiatives, particularly those in Jamésie, Quebec. Instead, Mosaic is setting its sights on more promising ventures in gold and nickel, specifically...